BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Elotuzumab: Interim Phase Ib/II data

Interim data from the Phase II portion of an open-label Phase Ib/II trial in 63 patients showed that 10 and 20 mg/kg doses of IV elotuzumab plus Revlimid lenalidomide and low-dose dexamethasone produced ORRs of 90% (28/31) and 72% (23/32), respectively. Grade 3/4...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >